CD274 and neoplasm: Secondly, the growing authorization of PD-1 and PD-L1 inhibitors for treating diverse tumor types (81, 82) has garnered significant attention to the combined utilization and effectiveness of anti-LAG-3 medicines and anti-PD-1 agents.